Skip to main content scroll back to top of page

Utility Navigation

Careers

Primary Navigation

Close Menu

Pipeline
- Our Pipeline
  Our PipelineOur Pipeline
  Oncology: Imipridones
  
  ONC201 dordaviprone for gliomas
  
  ONC206 for central nervous system tumors
  
  ONC212 IND-enabling studies
  
  Publications Presentations Neuro Oncology Publications 2024 SNO Annual Conference
Company
Patients
- Expanded Access
- Clinical Trials
Products
- TEMBEXA®
Investors
Contact

« All Publications

imipridones

Metabolic reprogramming by dual AKT/ERK inhibition through imipridones elicits unique vulnerabilities in glioblastoma

Clin Cancer Res. 2018 PMID: 30037819

View Publication

Chimerix on LinkedIn
Chimerix on Twitter

Legal Menu

Privacy Notice
Cookie Notice
Terms & Conditions of Use
Forward-Looking Statements
Community Guidelines
References

© 2024 Copyright Chimerix. All rights reserved.